$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000106282216000065 Filed on May 05, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$20.09M	$12.49M	$1.792M
YoY Change	5242.82%	597.21%	546.93%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$20.09M	$12.49M
YoY Change
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$8.416M	$8.398M	$5.700M
YoY Change	33.59%	47.33%	7.55%
% of Gross Profit	41.89%	67.22%
Research & Development	$48.22M	$37.00M	$20.87M
YoY Change	132.15%	77.34%	-12.89%
% of Gross Profit	240.01%	296.16%
Depreciation & Amortization	$500.0K	$521.0K	$355.0K
YoY Change	150.0%	46.76%	-44.88%
% of Gross Profit	2.49%	4.17%
Operating Expenses	$57.11M	$46.37M	$28.32M
YoY Change	111.02%	63.72%	-7.9%
Operating Profit	-$37.02M	-$33.87M	-$26.53M
YoY Change	38.72%	27.69%	-12.95%
Interest Expense	$1.638M	$1.649M	$1.702M
YoY Change	-1.03%	-3.11%	272.43%
% of Operating Profit
Other Income/Expense, Net	$547.0K	$637.0K	$153.0K
YoY Change	103.35%	316.34%	62.77%
Pretax Income	-$38.11M	-$34.88M	-$28.10M
YoY Change	35.63%	24.14%	-8.77%
Income Tax
% Of Pretax Income
Net Earnings	-$38.11M	-$34.88M	-$28.08M
YoY Change	35.76%	24.24%	-8.95%
Net Earnings / Revenue	-189.72%	-279.2%	-1566.74%
Basic Earnings Per Share			-$0.27
Diluted Earnings Per Share	-$367.1K	-$336.5K	-$0.27
COMMON SHARES
Basic Shares Outstanding	103.8M shares	103.8M shares	103.5M shares
Diluted Shares Outstanding			103.5M shares

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$429.4M	$477.1M	$314.7M
YoY Change	52.22%	51.6%	221.45%
Cash & Equivalents	$38.41M	$24.68M	$41.96M
Short-Term Investments	$391.0M	$452.5M	$272.7M
Other Short-Term Assets	$9.071M	$14.27M	$3.194M
YoY Change	26.85%	346.81%	-51.39%
Inventory
Prepaid Expenses
Receivables	$1.018M	$741.0K	$170.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$439.5M	$492.2M	$342.3M
YoY Change	40.04%	43.78%	224.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.35M	$20.75M	$732.0K
YoY Change	2875.15%	2735.11%	-98.17%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$53.36M	$53.36M	$53.36M
YoY Change	0.0%	0.0%	-0.37%
Long-Term Investments
YoY Change
Other Assets	$430.0K	$530.0K	$3.740M
YoY Change	-87.99%	-85.83%	2712.03%
Total Long-Term Assets	$118.7M	$119.2M	$102.4M
YoY Change	16.17%	16.42%	-25.92%
TOTAL ASSETS
Total Short-Term Assets	$439.5M	$492.2M	$342.3M
Total Long-Term Assets	$118.7M	$119.2M	$102.4M
Total Assets	$558.1M	$611.3M	$444.7M
YoY Change	34.18%	37.48%	82.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$28.23M	$25.54M	$12.14M
YoY Change	149.98%	110.38%	71.69%
Accrued Expenses	$23.95M	$23.62M	$11.77M
YoY Change	121.62%	100.65%	48.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$17.29M	$2.020M	$19.71M
YoY Change	-10.21%	-89.75%	1028.92%
Total Short-Term Liabilities	$131.0M	$121.9M	$45.93M
YoY Change	200.64%	165.48%	159.9%
LONG-TERM LIABILITIES
Long-Term Debt	$84.91M	$100.6M	$87.50M
YoY Change	-2.96%	14.91%	343.91%
Other Long-Term Liabilities	$14.04M	$14.59M	$23.26M
YoY Change	-39.06%	-37.26%	-31.63%
Total Long-Term Liabilities	$98.95M	$115.1M	$110.8M
YoY Change	-10.49%	3.96%	106.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$131.0M	$121.9M	$45.93M
Total Long-Term Liabilities	$98.95M	$115.1M	$110.8M
Total Liabilities	$340.8M	$358.5M	$187.1M
YoY Change	84.73%	91.61%	81.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.182B	-$1.144B	-$1.132B
YoY Change	1.86%	1.01%	9.43%
Common Stock	$104.0K	$104.0K	$727.0K
YoY Change	0.0%	-85.69%	40.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.368M	$3.368M	$2.747M
YoY Change	22.61%	22.61%	14.94%
Treasury Stock Shares	306.0K shares	306.0K shares	1.662M shares
Shareholders Equity	$217.3M	$252.9M	$257.6M
YoY Change
Total Liabilities & Shareholders Equity	$558.1M	$611.3M	$444.7M
YoY Change	34.18%	37.48%	82.55%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$38.11M	-$34.88M	-$28.08M
YoY Change	35.76%	24.24%	-8.95%
Depreciation, Depletion And Amortization	$500.0K	$521.0K	$355.0K
YoY Change	150.0%	46.76%	-44.88%
Cash From Operating Activities	-$47.90M	-$43.74M	-$23.49M
YoY Change	48.76%	86.25%	-22.54%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$54.00K	$17.00K
YoY Change	-100.0%	217.65%	-39.29%
Acquisitions
YoY Change
Other Investing Activities	$61.60M	-$133.6M	-$71.00M
YoY Change	7600.0%	88.17%	-274.88%
Cash From Investing Activities	$61.50M	-$133.6M	-$70.99M
YoY Change	20400.0%	88.25%	-274.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$437.0K	$357.0K
YoY Change		22.41%	-55.98%
Debt Paid & Issued, Net		$491.0K	$456.0K
YoY Change		7.68%	8.57%
Cash From Financing Activities	0.000	-$928.0K	-$830.0K
YoY Change	-100.0%	11.81%	-32.58%
NET CHANGE
Cash From Operating Activities	-47.90M	-$43.74M	-$23.49M
Cash From Investing Activities	61.50M	-$133.6M	-$70.99M
Cash From Financing Activities	0.000	-$928.0K	-$830.0K
Net Change In Cash	13.60M	-$178.3M	-$95.31M
YoY Change	-142.11%	87.09%	-1156.84%
FREE CASH FLOW
Cash From Operating Activities	-$47.90M	-$43.74M	-$23.49M
Capital Expenditures	$0.00	$54.00K	$17.00K
Free Cash Flow	-$47.90M	-$43.79M	-$23.50M
YoY Change	51.1%	86.34%	-22.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
CY2015Q1	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	1700000	USD
CY2016Q1	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	100000	USD
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	103821416	shares
CY2016Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2016Q1	lxrx	Buildings Collateral BuildingsCollateral	59100000	USD
CY2015Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	1753000	USD
CY2016Q1	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	965000	USD
CY2015Q2	lxrx	Common Stock Shares Authorized After Reverse Stock Split CommonStockSharesAuthorizedAfterReverseStockSplit	225000000	shares
CY2015Q2	lxrx	Common Stock Shares Authorized Before Reverse Stock Split CommonStockSharesAuthorizedBeforeReverseStockSplit	900000000	shares
CY2016Q1	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
CY2014Q4	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	34000000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2016Q1	lxrx	Land Collateral LandCollateral	2700000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	1092946	shares
CY2016Q1	lxrx	Real Estate Selling Price RealEstateSellingPrice	21200000	USD
CY2015Q4	lxrx	Reclassificationof Debt Issuance Costs Impactto Current Portionof Longterm Debt ReclassificationofDebtIssuanceCostsImpacttoCurrentPortionofLongtermDebt	39000	USD
CY2015Q4	lxrx	Reclassificationof Debt Issuance Costs Impactto Longterm Debt ReclassificationofDebtIssuanceCostsImpacttoLongtermDebt	2800000	USD
CY2015Q4	lxrx	Reclassificationof Debt Issuance Costs Impactto Other Assets ReclassificationofDebtIssuanceCostsImpacttoOtherAssets	2900000	USD
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Sanofi Developmentand Regulatory Milestone Payments SanofiDevelopmentandRegulatoryMilestonePayments	430000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Development Deliverable SanofiRevenueAllocatedtoDevelopmentDeliverable	113800000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Funding Deliverable SanofiRevenueAllocatedtoFundingDeliverable	59400000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto License Deliverable SanofiRevenueAllocatedtoLicenseDeliverable	126800000	USD
CY2016Q1	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	12000000	USD
CY2015Q4	lxrx	Sanofi Sales Milestone Payments SanofiSalesMilestonePayments	990000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
CY2015Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	849000	USD
CY2016Q1	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	846000	USD
CY2015Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1104000	USD
CY2016Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	989000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	1891074	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2014Q4	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	5800000	USD
CY2015Q2	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	750000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2014Q4	lxrx	Symphony Contingent Payment Total SymphonyContingentPaymentTotal	11500000	USD
CY2014Q4	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	666111	shares
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19725000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	25544000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	911000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	741000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24757000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23615000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	59428000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58339000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-219000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	297000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1397646000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1399665000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1953000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1835000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1800000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2015Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	62000	USD
CY2016Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	125000	USD
CY2015Q4	us-gaap	Assets Assets	651960000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34367000	USD
CY2016Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24681000	USD
CY2016Q1	us-gaap	Assets Assets	611341000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	532400000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	492158000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137266000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41960000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202989000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-95306000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-178308000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	104000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27990000	USD
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2016Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	144700000	USD
CY2016Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0823
CY2014Q4	us-gaap	Debt Issuance Costs DebtIssuanceCosts	3400000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	76499000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	70764000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	109151000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	102699000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2016Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	18675000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	355000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	521000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1753000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	965000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-750000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17638000	USD
CY2015Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	18641000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22815000	USD
CY2016Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23780000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	6000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	12000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5701000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8398000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2016Q1	us-gaap	Goodwill Goodwill	44543000	USD
CY2016Q1	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	4100000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1302000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3836000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4134000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-865000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-170000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	278000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12187000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-393000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1570000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	53357000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1702000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	1649000	USD
CY2015Q1	us-gaap	Interest Paid Net InterestPaidNet	412000	USD
CY2016Q1	us-gaap	Interest Paid Net InterestPaidNet	378000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	366110000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	358460000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	651960000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	611341000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	122957000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	121943000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1976000	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2020000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100960000	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	100550000	USD
CY2016Q1	us-gaap	Mortgage Loans On Real Estate Carrying Amount Of Mortgages MortgageLoansOnRealEstateCarryingAmountOfMortgages	17800000	USD
CY2004Q2	us-gaap	Mortgage Loans On Real Estate New Mortgage Loans MortgageLoansOnRealEstateNewMortgageLoans	34000000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-830000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-928000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70991000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133640000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23485000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43740000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-28076000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-34883000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	28319000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	46365000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26527000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-33871000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10137000	USD
CY2016Q1	us-gaap	Other Assets Current OtherAssetsCurrent	14271000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	433000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	530000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	86000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	516000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14367000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14593000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	153000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	637000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	357000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	621000	USD
CY2015Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	70978000	USD
CY2016Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	208986000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	54000	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	184000	USD
CY2015Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-17000	USD
CY2016Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2015Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2016Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	75400000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	USD
CY2016Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21227000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20753000	USD
CY2015Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	456000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	491000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20865000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37002000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1108934000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1143817000	USD
CY2015Q1	us-gaap	Revenues Revenues	1792000	USD
CY2016Q1	us-gaap	Revenues Revenues	12494000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1953000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1835000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	318363000	USD
CY2016Q1	us-gaap	Short Term Investments ShortTermInvestments	452465000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2016Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	184000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	285850000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	252881000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	284018000	USD
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	257607000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	285850000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	252881000	USD
CY2015Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	-17000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	237000	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	306000	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2747000	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	3368000	USD
CY2015Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	357000	USD
CY2016Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	621000	USD
CY2016Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2700000	USD
CY2015Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	86000	USD
CY2016Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	516000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103516000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103682000	shares

Files In Submission

Name	View Source	Status
0001062822-16-000065-index-headers.html	Edgar Link	pending
0001062822-16-000065-index.html	Edgar Link	pending
0001062822-16-000065.txt	Edgar Link	pending
0001062822-16-000065-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20160331.xml	Edgar Link	completed
lxrx-20160331.xsd	Edgar Link	pending
lxrx-20160331_cal.xml	Edgar Link	unprocessable
lxrx-20160331_def.xml	Edgar Link	unprocessable
lxrx-20160331_lab.xml	Edgar Link	unprocessable
lxrx-20160331_pre.xml	Edgar Link	unprocessable
lxrx331201610-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2016 Q2 Form 10-Q Financial Statement

#000106282216000065 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2016 Q2 Form 10-Q Financial Statement

#000106282216000065 Filed on May 05, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx